ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1599

Performance of Referral Strategies for Spondyloarthritis: A Population-Based Nationwide Study

Alexandre Sepriano1,2, Sofia Ramiro1,2, Filipe Araújo3, Pedro Machado4, Ana M. Rodrigues1,5, Nélia Gouveia1,5, Mónica Eusébio5, Helena Canhão5,6 and Jaime Cunha Branco1,5, 1CEDOC, NOVA Medical School, Lisbon, Portugal, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Hospital Ortopédico de Sant ‘Ana, Cascais, Portugal, 4University College London - MRC Centre for Neuromuscular Diseases, London, United Kingdom, 5EpiReumaPt Study Group, Lisbon, Portugal, 6EPIDOC, Nova Medical School, Faculdade Ciências Médicas, Lisboa, Portugal

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Referrals and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Several strategies have been proposed to promote early referral of patients with SpA, but consensus on the ‘best’ strategy is yet to be achieved. Moreover, few studies compared referral strategies (RS) head-to-head and none has neither evaluated these in a ‘nationwide’ setting (external validity) nor assessed the entire spectrum of SpA (i.e. axSpA and peripheral SpA). We aimed to evaluate the performance of the screening strategy for SpA of a nationwide epidemiological study (EpiReumaPt), as compared to previously proposed RS.

Methods: EpiReumaPt was a three-stage national health survey (2011-2013) where, in the first phase, 10,661 adult participants were randomly selected and interviewed using a structured face-to-face questionnaire that included screening for rheumatic diseases (RD), such as SpA. In the second phase, positive screenings for ≥1 rheumatic complaint plus 20% negative screenings were invited for an assessment by the rheumatologist. Finally, 3 rheumatologists revised all the information and defined the final diagnosis by consensus. All participants of the second phase were included (N=3,877). Each RS (table) was tested against the SpA revised diagnosis using the following metrics: sensitivity, specificity, positive predictive value (PPV), and post-test probability of disease given a negative test (1-negative predictive value). RS with an imaging (e.g. MRI) or laboratory component (e.g. CRP, HLA-B27) were modified (by excluding these components) given limited data obtained in the survey (table). A weighting factor was used to take the survey design into account.

Results: From the total 3,877 participants, 92 received a SpA diagnosis [weighted prevalence: 1.6% (95%CI: 1.2; 2.1)], 3,107 other RD diagnosis [e.g. knee osteoarthritis (31%)] and 678 no RD diagnosis. The ASAS RS was the most sensitive (85%) followed by the EpiReumaPt strategy (72%) (Table). The ASAS and EpiReumaPt RS had the lowest post-test probabilities of SpA in the presence of negative screening (0.6% and 0.7% respectively), thus, yielding a marked decrease in the probability of disease if negative [(1.6-0.6)/1.6*100=63%; (1.6-0.7)/1.6*100=56% respectively). On the other hand, the likelihood of SpA increased by 38% (2.2-1.6)/1.6*100) and 119% (3.5-1.6)/1.6*100) in case of a positive ASAS and EpiReumaPt RS, respectively. Brandt III was the least sensitive strategy in this study and not contributive to excluding SpA (1-NPV: 1.5%; pre-test probability: 1.6%), but expectedly increased the likelihood of SpA by 3.8 times if positive. The performance of the remaining RS is described in the table.

Conclusion: For the first time, a wide range of SpA RS were tested in a population-based setting where the ASAS and EpiReumaPt RS were shown to be the most sensitive. Our data suggest that these strategies can be effectively used as screening tools for SpA especially when laboratory and imaging data are not available.

Uma imagem com texto, captura de ecrã Descrição gerada com confiança muito alta


Disclosure: A. Sepriano, None; S. Ramiro, None; F. Araújo, None; P. Machado, None; A. M. Rodrigues, None; N. Gouveia, None; M. Eusébio, None; H. Canhão, None; J. C. Branco, None.

To cite this abstract in AMA style:

Sepriano A, Ramiro S, Araújo F, Machado P, Rodrigues AM, Gouveia N, Eusébio M, Canhão H, Branco JC. Performance of Referral Strategies for Spondyloarthritis: A Population-Based Nationwide Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/performance-of-referral-strategies-for-spondyloarthritis-a-population-based-nationwide-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-referral-strategies-for-spondyloarthritis-a-population-based-nationwide-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology